Owens & Minor reports Q3 results as it moves forward with Patient Direct

RICHMOND, Va. – Owens & Minor reported revenue of $697.3 million for the third quarter of 2025, compared to $686.8 million for the prior year quarter. 

Adjusted EDITDA was $92.2 million, compared to $107.7 million the prior year.

The results represent the company’s continuing operations, which primarily represent what was previously the Patient Direct segment and certain functional operations.  

Owens & Minor announced in October it had signed a definitive agreement to sell its Products & Healthcare Services (P&HS) segment to Platinum Equity for $375 million in cash. 

“Our recent announcement on the sale of our Products & Healthcare Services segment is another meaningful step in our strategy to pivot our focus to the more attractive home-based care space,” said Edward Pesicka, president & CEO. “We are keenly focused on reshaping our organization as one built around our Patient Direct platform and the long-term growth opportunities within home-based care. An example of this focus on growth is our recently announced nationwide preferred provider partnership agreement.” 

“Looking ahead, we will be a simpler, stronger company that is better positioned to execute on our mission of serving patients with chronic conditions in the home and are excited about the next chapter for our business,” he continued. “We are confident that the breadth of our offerings and our nationwide reach provide a unique capability to succeed in the future of home-based care. With our focus now centered entirely on Patient Direct, our capital deployment, strategic direction, and execution are unified to drive sustainable growth and long-term value creation.” 

Owens & Minor provided the following 2025 continuing operations outlook: 

• Revenue of between $2.76 billion and $2.82 billion 
• Adjusted EPS ranging between $1.02 to $1.07 
• Adjusted EBITDA range of $376 million to $382 million 

Related reading:

Owens & Minor refocuses on Patient Direct